首页> Toxicological sciences : an official journal of the Society of Toxicology> Qualified kidney injury biomarkers demonstrate value during early clinical drug development.

Qualified kidney injury biomarkers demonstrate value during early clinical drug development.

导出原文传递

翻译打印收藏纠错

第一作者： Kodihalli C,Ravindra

第一单位： Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States.

作者： Kodihalli C,Ravindra ^[1] ; Kelly A,Fader ^[2] ; David,Potter ^[3] ; Zaher A,Radi ^[4] ; Gary S,Friedman ^[5] ; Karrie A,Brenneman ^[4] ; Neeta B,Amin ^[6] ; Roberta,Weiss ^[5] ; Spencer I,Danto ^[7] ; Karen,Page ^[8] ; Shashi K,Ramaiah ^[4] ; Vishal S,Vaidya ^[4]

作者单位： Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States. ^[1] Department of Translational Clinical Sciences, Pfizer Inc., Groton, CT 06340, United States. ^[2] Department of Global Biometrics and Data Management, Pfizer Inc., Cambridge, MA 02139, United States. ^[3] Department of Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, United States. ^[4] Department of Inflammation and Immunology, Pfizer Inc., Collegeville, PA 19426, United States. ^[5] Department of Internal Medicine, Pfizer Inc., Cambridge, MA 02139, United States. ^[6] Department of Inflammation and Immunology, Pfizer Inc., Cambridge, MA 02139, United States. ^[7] Department of Translational Clinical Sciences, Pfizer Inc., Cambridge, MA 02140, United States. ^[8]

关键词 kidney toxicity kidney tubular injury qualified biomarkers safety de-risking